{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:35Z","timestamp":1793734115009,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paula and Rodger Riney Foundation International Myeloma Society translational award","id":[{"id":"https:\/\/ror.org\/00mwgwn78","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"fellowship (project number ZZ-40) of the Interdisciplinary Center for Clinical Research"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC\/TRR 338, Z02"],"award-info":[{"award-number":["CRC\/TRR 338, Z02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paula and Rodger Riney Foundation Leukemia Lymphoma Society","id":[{"id":"https:\/\/ror.org\/050a7g229","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Advanced Medical Scientist Program of Heidelberg University"},{"name":"Memorial Sloan Kettering Cancer Center NCI Core Grant","id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04175-8","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:06:12Z","timestamp":1768471572000},"page":"964-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma"],"prefix":"10.1038","volume":"32","author":[{"given":"Holly","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-6843","authenticated-orcid":false,"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerone A.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-7127","authenticated-orcid":false,"given":"Noemie","family":"Leblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1769-571X","authenticated-orcid":false,"given":"Dylan","family":"Greening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"Colarusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Canton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Benaoudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0496","authenticated-orcid":false,"given":"Elham","family":"Hasheminasabgorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Poorebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1390-6699","authenticated-orcid":false,"given":"David","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Truger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5567-4753","authenticated-orcid":false,"given":"Jihong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Somandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara-Sheena","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hendrik","family":"Frenking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-3234","authenticated-orcid":false,"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0954-3908","authenticated-orcid":false,"given":"Konstantina","family":"Taouxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6481-1716","authenticated-orcid":false,"given":"Yunje","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"4175_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. New Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"New Engl. J. Med."},{"key":"4175_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"4175_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N. J. et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat. Med. 29, 2570\u20132576 (2023).","journal-title":"Nat. Med."},{"key":"4175_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting gprc5d bispecific antibody for multiple myeloma. New Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"New Engl. J. Med."},{"key":"4175_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"New Engl. J. Med."},{"key":"4175_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4175_CR7","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, A. et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 40, 3576\u20133586 (2022).","journal-title":"J. Clin. Oncol."},{"key":"4175_CR8","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2019-126818","volume":"134","author":"D Cooper","year":"2019","unstructured":"Cooper, D. et al. Safety and preliminary clinical activity of REGN5458, an anti-BCMA x anti-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Blood 134, 3176 (2019).","journal-title":"Blood"},{"key":"4175_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella, C. et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (iv) and first subcutaneous (sc) results from a phase I dose-escalation study. Blood 140, 397\u2013399 (2022).","journal-title":"Blood"},{"key":"4175_CR10","doi-asserted-by":"crossref","unstructured":"Harrison, S. J. et al. Efficacy of forimtamig, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analysis of patient- and disease-related factors associated with responses. Clin. Lymphoma Myeloma Leuk. 23 (S3\u2013S4), Abstract OA-05 (2023).","DOI":"10.1016\/S2152-2650(23)01572-0"},{"key":"4175_CR11","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke, C. D. et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8036 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4175_CR12","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger, M. S. et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 5, 3794\u20133798 (2021).","journal-title":"Blood Adv."},{"key":"4175_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 (2023).","journal-title":"Nat. Med."},{"key":"4175_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"4175_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"4175_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2024026622","volume":"146","author":"S Ma","year":"2025","unstructured":"Ma, S. et al. Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma. Blood 146, 178\u2013190 (2025).","journal-title":"Blood"},{"key":"4175_CR17","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. New Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"New Engl. J. Med."},{"key":"4175_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO-24-01785","volume":"43","author":"EM Jurgens","year":"2025","unstructured":"Jurgens, E. M. et al. Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis. J. Clin. Oncol. 43, 498\u2013504 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4175_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMc2308544","volume":"389","author":"X Mi","year":"2023","unstructured":"Mi, X., Penson, A., Abdel-Wahab, O. & Mailankody, S. Genetic basis of relapse after GPRC5D-targeted CAR T cells. New Engl. J. Med. 389, 1435\u20131437 (2023).","journal-title":"New Engl. J. Med."},{"key":"4175_CR20","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien, J. et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat. Cancer 4, 1536\u20131543 (2023).","journal-title":"Nat. Cancer"},{"key":"4175_CR21","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet. Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet. Oncol."},{"key":"4175_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"4175_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol"},{"key":"4175_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbamem.2006.09.008","volume":"1768","author":"C Dong","year":"2007","unstructured":"Dong, C., Filipeanu, C. M., Duvernay, M. T. & Wu, G. Regulation of G protein-coupled receptor export trafficking. Biochim. Biophys. Acta 1768, 853\u2013870 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"4175_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue, S., Nambu, T. & Shimomura, T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J. Invest. Dermatol. 122, 565\u2013573 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"4175_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1210\/er.2013-1121","volume":"35","author":"YX Tao","year":"2014","unstructured":"Tao, Y. X. & Conn, P. M. Chaperoning G protein-coupled receptors: from cell biology to therapeutics. Endocr. Rev. 35, 602\u2013647 (2014).","journal-title":"Endocr. Rev."},{"key":"4175_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev.pharmtox.44.101802.121558","volume":"44","author":"CM Tan","year":"2004","unstructured":"Tan, C. M., Brady, A. E., Nickols, H. H., Wang, Q. & Limbird, L. E. Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 44, 559\u2013609 (2004).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"4175_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.gendis.2015.02.005","volume":"2","author":"H Stoy","year":"2015","unstructured":"Stoy, H. & Gurevich, V. V. How genetic errors in GPCRs affect their function: possible therapeutic strategies. Genes Dis. 2, 108\u2013132 (2015).","journal-title":"Genes Dis."},{"key":"4175_CR29","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti, K. et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135, 1232\u20131243 (2020).","journal-title":"Blood"},{"key":"4175_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","volume":"145","author":"J Eckmann","year":"2025","unstructured":"Eckmann, J. et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood 145, 202\u2013219 (2025).","journal-title":"Blood"},{"key":"4175_CR31","unstructured":"Center for Drug Evaluation and Research. NDA\/BLA Multi-disciplinary Review and Evaluation {BLA 761342}, application number 761342Orig1s000 (2022)."},{"key":"4175_CR32","doi-asserted-by":"publisher","first-page":"168748","DOI":"10.1016\/j.jmb.2024.168748","volume":"436","author":"J Jeong","year":"2024","unstructured":"Jeong, J., Park, J., Young Mo, G., Shin, J. & Cho, Y. Structural basis for the recognition of GPRC5D by talquetamab, a bispecific antibody for multiple myeloma. J. Mol. Biol. 436, 168748 (2024).","journal-title":"J. Mol. Biol."},{"key":"4175_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55143-0","volume":"14","author":"U Tomita","year":"2024","unstructured":"Tomita, U. et al. A novel T cell-redirecting anti-GPRC5D\u00d7CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models. Sci. Rep. 14, 5135 (2024).","journal-title":"Sci. Rep."},{"key":"4175_CR34","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5D\u00d7CD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215 (2021).","journal-title":"Blood Adv."},{"key":"4175_CR35","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl. Med."},{"key":"4175_CR36","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood-2024-205481","volume":"144","author":"T Jelinek","year":"2024","unstructured":"Jelinek, T. et al. Depletion of mature B cells and of normal plasma cells (PC) behind the higher incidence of infections after anti-BCMA VS anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM). Blood 144, 1934 (2024).","journal-title":"Blood"},{"key":"4175_CR37","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta, V. A. et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 137, 3604\u20133615 (2021).","journal-title":"Blood"},{"key":"4175_CR38","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1111\/cas.15073","volume":"112","author":"A Kitadate","year":"2021","unstructured":"Kitadate, A. et al. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci. 112, 3645\u20133654 (2021).","journal-title":"Cancer Sci."},{"key":"4175_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.2023020276","volume":"143","author":"N Leblay","year":"2024","unstructured":"Leblay, N. et al. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood 143, 42\u201356 (2024).","journal-title":"Blood"},{"key":"4175_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41588-021-00790-6","volume":"53","author":"JM Granja","year":"2021","unstructured":"Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet. 53, 403\u2013411 (2021).","journal-title":"Nat. Genet."},{"key":"4175_CR41","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2014.11.021","volume":"159","author":"SS Rao","year":"2014","unstructured":"Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665\u20131680 (2014).","journal-title":"Cell"},{"key":"4175_CR42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.pharmthera.2006.02.008","volume":"111","author":"YX Tao","year":"2006","unstructured":"Tao, Y. X. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol. Ther. 111, 949\u2013973 (2006).","journal-title":"Pharmacol. Ther."},{"key":"4175_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w","volume":"10","author":"T Nerreter","year":"2019","unstructured":"Nerreter, T. et al. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat. Commun. 10, 3137 (2019).","journal-title":"Nat. Commun."},{"key":"4175_CR44","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1538-7445.AM2023-1875","volume":"83","author":"F Li","year":"2023","unstructured":"Li, F. et al. Abstract 1875: A novel T-cell-engaging therapeutical antibody against GPRC5D&BCMA for multiple myeloma treatment. Cancer Res. 83, 1875\u20131875 (2023).","journal-title":"Cancer Res."},{"key":"4175_CR45","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","volume":"43","author":"NWCJVD Donk","year":"2025","unstructured":"Donk, N. W. C. J. V. D. et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results. J. Clin. Oncol. 43, 7505\u20137505 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4175_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea, C. et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146\u2013154 (2020).","journal-title":"Blood Cancer Discov."},{"key":"4175_CR47","doi-asserted-by":"publisher","unstructured":"Duffy, A. M. et al. Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapy. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci192927 (2025).","DOI":"10.1172\/jci192927"},{"key":"4175_CR48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva, D. et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood 144, 615\u2013628 (2024).","journal-title":"Blood"},{"key":"4175_CR49","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"4175_CR50","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).","journal-title":"PLoS Med."},{"key":"4175_CR51","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"TU Consortium","year":"2022","unstructured":"Consortium, T. U. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51, D523\u2013D531 (2022).","journal-title":"Nucleic Acids Res."},{"key":"4175_CR52","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/bioinformatics\/btt607","volume":"30","author":"U Omasits","year":"2013","unstructured":"Omasits, U., Ahrens, C. H., M\u00fcller, S. & Wollscheid, B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 30, 884\u2013886 (2013).","journal-title":"Bioinformatics"},{"key":"4175_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 1, 258\u2013273 (2020).","journal-title":"Blood Cancer Discov."},{"key":"4175_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25469-8","volume":"12","author":"KH Maclachlan","year":"2021","unstructured":"Maclachlan, K. H. et al. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nat. Commun. 12, 5172 (2021).","journal-title":"Nat. Commun."},{"key":"4175_CR55","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1093\/nar\/gkw491","volume":"44","author":"R Xi","year":"2016","unstructured":"Xi, R., Lee, S., Xia, Y., Kim, T. M. & Park, P. J. Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants. Nucleic Acids Res. 44, 6274\u20136286 (2016).","journal-title":"Nucleic Acids Res."},{"key":"4175_CR56","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"4175_CR57","doi-asserted-by":"publisher","first-page":"15.19.11","DOI":"10.1002\/cpbi.17","volume":"56","author":"KM Raine","year":"2016","unstructured":"Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinform. 56, 15.19.11\u201315.19.17 (2016).","journal-title":"Curr. Protoc. Bioinform."},{"key":"4175_CR58","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1093\/bioinformatics\/bty388","volume":"34","author":"J Shinde","year":"2018","unstructured":"Shinde, J. et al. Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics 34, 3380\u20133381 (2018).","journal-title":"Bioinformatics"},{"key":"4175_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s42003-021-01938-0","volume":"4","author":"EH Rustad","year":"2021","unstructured":"Rustad, E. H. et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun. Biol. 4, 424 (2021).","journal-title":"Commun. Biol."},{"key":"4175_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0539-0","volume":"10","author":"F Blokzijl","year":"2018","unstructured":"Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 10, 33 (2018).","journal-title":"Genome Med."},{"key":"4175_CR61","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029\u20131041.e1021 (2017).","journal-title":"Cell"},{"key":"4175_CR62","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"4175_CR63","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"4175_CR64","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"4175_CR65","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1101\/gr.080531.108","volume":"19","author":"KD Pruitt","year":"2009","unstructured":"Pruitt, K. D. et al. The Consensus Coding Sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes. Genome Res. 19, 1316\u20131323 (2009).","journal-title":"Genome Res."},{"key":"4175_CR66","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/ijc.32639","volume":"146","author":"T Robin","year":"2020","unstructured":"Robin, T., Capes-Davis, A. & Bairoch, A. CLASTR: the Cellosaurus STR similarity search tool - a precious help for cell line authentication. Int. J. Cancer 146, 1299\u20131306 (2020).","journal-title":"Int. J. Cancer"},{"key":"4175_CR67","doi-asserted-by":"publisher","unstructured":"Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.10.04.463034 (2022).","DOI":"10.1101\/2021.10.04.463034"},{"key":"4175_CR68","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679\u2013682 (2022).","journal-title":"Nat. Methods"},{"key":"4175_CR69","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D"},{"key":"4175_CR70","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04175-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:54Z","timestamp":1774018974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04175-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04175-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.B. has received research funding from Pfizer, and received speaker\u2019s bureau honoraria from Amgen, BMS, Sanofi, Pfizer and Janssen and is a consultant\/advisory board member for BMS, Janssen and Pfizer. P.N. received speaker\u2019s bureau honoraria from BMS, Janssen and Sanofi and is a consultant\/advisory board member for BMS and Janssen. D.V. and S.S. are employees of Johnson & Johnson and may hold stock, stock options or equity in Johnson & Johnson. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}